Relationship of body mass index and waist circumference with clinical outcomes following percutaneous coronary intervention

Yonggu Lee1*, Uram Jin2*, Won Moo Lee3, Hong-Seok Lim2*, Young-Hyo Lim4*

1 Department of Cardiology, Hanyang University Guri Hospital, Guri, Gyeonggi-do, Republic of Korea, 2 Department of Cardiology, Ajou University School of Medicine, Suwon, Gyeonggi-do, Republic of Korea, 3 Department of Obstetrics and Gynecology, Hanyang University College of Medicine, Seoul, Republic of Korea, 4 Division of Cardiology, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea

☯ These authors contributed equally to this work.
* mdoim@hanyang.ac.kr (YHL); camdhslim@ajou.ac.kr (HSL)

Abstract

Background

A biphasic, U-shape relationship has been reported between body mass index (BMI) and clinical outcomes following percutaneous coronary intervention (PCI). However, the relationship between waist circumference (WC) and the cardiovascular risk following PCI has not been reported.

Methods

A prospective cohort study was performed. A major adverse cardiac event (MACE) was defined as a composite of cardiac death (CD), nonfatal myocardial infarction (NFMI) and target vessel revascularization (TVR). Patients were evenly divided into 4 groups according to BMI (Q1BMI, Q2BMI, Q3BMI and Q4BMI) and WC (Q1WC, Q2WC, Q3WC and Q4WC).

Results

A total of 1,421 patients were observed for 5 years. The risk of the composite events of CD and NFMI (CD/NFMI) was lower in the Q3WC and Q4WC groups than in the Q1WC group, whereas it was only marginally lower in the Q2BMI group than in the Q1BMI group (ANOVA, p = 0.062). The risk of MACE was highest in the Q1WC group and lowest in the Q3WC group; however, the risk of MACE did not differ among the 4 groups, according to BMI. Multivariate Cox-regression analyses showed that the risk of CD/NFMI gradually decreased with BMI (linear p = 0.030) and with WC (linear p = 0.015). The risks of TVR and MACEs that were driven by TVRs showed a distinguishing biphasic, U-shaped relationship with WC (nonlinear p = 0.009) but not with BMI (nonlinear p = 0.439). Landmark survival analysis showed that the incidences of CD and NFMI were higher in the lower BMI groups and lower WC groups than in the higher BMI groups and higher WC groups, respectively, until 1 year and did not differ afterward. In contrast, the incidence of MACE was highest in Q1WC and lowest in Q3WC (log-rank p = 0.003), whereas the incidence was not different among the groups according to BMI.
Conclusions
Both BMI and WC were associated with a lower risk of early episodes of CD and NFMI after PCI. In the late period after PCI, WC demonstrated a biphasic, U-shaped association between cardiovascular outcomes and adiposity, whereas BMI did not.

Introduction
Obesity is a well-known risk factor for cardiovascular disease (CVD) and mortality in the general population [1–3]. Obesity is associated with worse major cardiovascular risk factors, including lipid profiles, blood pressure and glucose levels; it also accelerates atherosclerotic processes and increases cardiovascular burden, which may lead to systolic and diastolic ventricular dysfunction [4, 5]. However, the paradoxical beneficial effects of mild to moderate obesity on clinical outcomes have been repeatedly reported in cardiovascular research [6]. Large-scale, population-based studies have shown J-curve relationships between body mass index (BMI) and the risk of CVDs and death [7]. Several studies have also reported a negative association between BMI and the rate of cardiovascular events after percutaneous coronary intervention (PCI) [8, 9]. One criticism of the paradoxical beneficial effect demonstrated in those studies is that high BMI may reflect not only high adiposity but also an abundance of skeletal muscles, which has been reported to be associated with lower mortality rates [10–13]. Waist circumference (WC), which indicates central adiposity and reflects little lean body mass, has been reported to be a better predictor of cardiovascular events and mortality than is BMI [14]. However, no study has reported a comparison of WC and BMI in relation to the clinical outcomes following PCI. Therefore, we comparatively investigated the influences of BMI and WC on cardiovascular outcomes in a prospective PCI registry.

Methods
Patients
From January 2009 to December 2013, a prospective cohort study was performed at two high-volume PCI centers located in Seoul and Suwon, Republic of Korea. Patients undergoing PCI with drug-eluting stents (DESs) were consecutively enrolled in the registry. Written informed consent was obtained from all patients before their enrollment in the study. The study protocol complied with the principles expressed in the Declaration of Helsinki. The Institutional Review Board of Hanyang University Medical Center approved the study protocol and monitored the study process (IRB No. HYUH 2017-11-031). Patients younger than 35 years of age, patients who had previously undergone coronary artery bypass surgery, patients who suffered from debilitating conditions, including advanced malignancies, advanced liver cirrhosis, end-stage renal disease, severe autoimmune diseases and cerebrovascular accidents with major sequelae, and patients with a life expectancy of less than 12 months were excluded. Information regarding demographic characteristics, past medical histories and social histories was obtained from all patients before they were registered. Lipid profiles, serum glucose levels and hemoglobin A1c levels were measured the morning before the index PCI, after the patients had fasted for 8 hours. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Diseases study equation, and chronic kidney disease (CKD) was defined as an eGFR \( \leq 60 \text{ ml/min/1.73 m}^2 \). Before the procedure, 300 mg of aspirin and P2Y12 inhibitors (600 mg of clopidogrel, 60 mg of prasugrel or 180 mg of ticagrelor) were
administered to all patients. After the index PCI, all patients received dual antiplatelet agent therapy (DAPT) for ≥1 year and high-intensity statin therapy indefinitely, unless they had contraindications to statin use.

**Measurements of height, weight and waist circumference**

Body weight, height and WC were usually determined on the day before the index PCI. In patients with acute coronary syndrome (ACS) and who had presented in emergency settings, body size measurements were obtained within 7 days after the index PCI. WC was measured in the mid portion between the lowest margin of the ribs and the highest part of the iliac crest when the patients were in a supine position and after the expiration of a breath.

**PCI and the definitions of clinical outcomes**

PCI was performed using standard techniques. A stenotic lesion that required PCI was defined as a lesion with luminal narrowing ≥70%, based on quantitative angiographic measurements. During the observation period, repeat coronary angiography was performed when patients presented with symptoms of angina or signs of myocardial ischemia. Standardized definitions of clinical events frequently used in cardiovascular trials were used, as described by Hicks et al [15]. Cardiac death (CD) included death resulting from acute myocardial infarction (MI), heart failure or cardiogenic shock. Myocardial infarction (MI) was defined as an increase in cardiac troponin I levels to a level at least 3 times the upper normal limit, with one or more clinical indicator of myocardial ischemia, including symptoms of angina, ST-segment changes on electrocardiography and wall motion abnormalities on echocardiography. Nonfatal MI (NFMI) was defined as an MI that did not result in CD. Target vessel revascularization (TVR) was defined as the performance of balloon angioplasty or stent implantation in the target vessel during the observation period. TVR was performed when a lesion with luminal narrowing ≥70% or functional ischemia was present in the target vessel territory on any diagnostic test. A major adverse cardiac event (MACE) was defined as a combination of CD, NFMI and TVR. PCIs for de novo stenotic lesions in nontarget coronary arteries were not considered to be TVR, and the first event that occurred during the observation period was used as the clinical event of a patient.

**Statistical analysis**

The patients were equally divided into 4 groups, according to BMI (Q1_{BMI}, Q2_{BMI}, Q3_{BMI} and Q4_{BMI}) and WC (Q1_{WC}, Q2_{WC}, Q3_{WC} and Q4_{WC}). Analysis of variance (ANOVA) was used to compare continuous variables, and a Chi-squared test was used to compare categorical variables among the 4 groups, based on each obesity index. A Kruskal-Wallis test was employed for variables with a skewed distribution. Kaplan-Meier survival analysis with a log-rank test was used to compare cumulative incidences of the clinical events among the 4 groups, based on BMI and WC. A 1-year landmark analysis was performed to evaluate the different influences of obesity indexes on short-term and long-term outcomes. Multiple Cox regression analysis with a stepwise variable selection process was performed to estimate the difference in the risk of clinical events among the 4 groups, based on BMI and WC. The nonlinear relationship between the obesity indexes as continuous variables and the risk of clinical events was evaluated using multiple Cox regression models, with a restrictive cubic spline function for the obesity indexes to evaluate changes in the pattern of associations between the obesity indexes and clinical outcomes. Comparison between a linear model and a nonlinear model was performed using ANOVA. Age, sex, diabetes mellitus, hypertension, CKD, current smoking, prior PCI, the diagnosis of ST-segment elevation MI (STEMI), the duration of DAPT, the number of
narrowed coronary arteries, stent type (1st vs. 2nd generation DES), total stent length, average stent diameter and complete revascularization were included in the multiple Cox regression models as covariates. All statistical analyses were performed using R-3.4.0 (from the R foundation for Statistical Computing), and \( p < 0.05 \) was considered to be statistically significant.

**Results**

**Baseline characteristics**

A total of 1,421 patients were observed for 3,390 person-years (2.38 years/person). The baseline and angiographic characteristics of the entire study population and patients in each BMI and WC group are described in Table 1 and S1 Table. Patient age decreased with BMI but not with WC. The prevalence of hypertension increased with both BMI and WC, whereas the prevalence of diabetes mellitus increased only with WC. The frequency of ACS decreased with BMI; however, it did not differ based on WC. The serum levels of hemoglobin, total cholesterol, LDL cholesterol, triglyceride and hemoglobin A1c increased with both BMI and WC. The left ventricular ejection fraction increased with BMI and WC; however, the increments among the groups were negligible. The number of narrowed coronary arteries, rate of complete revascularization, number of stents implanted, average stent diameter, total stent length, stent types and frequency of 2nd generation DES use did not differ based on BMI and WC. There was a moderate correlation between BMI and WC (\( r = 0.68, p < 0.001 \)).

**Comparison of clinical outcomes among the groups**

The median observation duration was 29 months (interquartile range: 13–41 months). The overall incidences of CD, NFMI, TVR and MACEs did not differ based on BMI. The overall incidences of TVR and MACEs were lowest in the Q3\textsubscript{WC} group (among the WC groups), whereas the overall incidences of CD and NFMI did not differ, based on WC (Fig 1 and S2 Table).

Kaplan-Meier survival curve analysis showed that the occurrence of CD and NFMI did not differ among the groups, based on BMI. CD was more frequent in the Q1\textsubscript{WC} and Q2\textsubscript{WC} groups than in the Q3\textsubscript{WC} and Q4\textsubscript{WC} groups. The occurrence of NFMI was marginally more frequent in the Q1\textsubscript{WC} and Q2\textsubscript{WC} groups than in the Q3\textsubscript{WC} and Q4\textsubscript{WC} groups (S1 Fig). The composite events of CD and NFMI (CD/NFMI) were most frequent in the Q1\textsubscript{BMI} and Q1\textsubscript{WC} groups and least frequent in the Q3\textsubscript{BMI} and Q3\textsubscript{WC} groups. The occurrence of TVR and MACEs did not differ among the BMI groups; however, it was highest in the Q1\textsubscript{WC} group and lowest in the Q3\textsubscript{WC} group among the groups stratified by WC (Fig 2).

Multiple Cox regression analysis showed that the risk of CD/NFMI was lower in the Q3\textsubscript{BMI} group than in the Q1\textsubscript{BMI} group, but there was no significant trend for the risk of CD/NFMI among the 4 BMI groups. The risk of CD/NFMI was lower in the Q3\textsubscript{WC} and Q4\textsubscript{WC} groups than in the Q1\textsubscript{WC} groups. The risk of MACEs was not significantly different among the BMI groups, whereas the risk of MACEs was lower in the Q3\textsubscript{WC} groups than in the Q1\textsubscript{WC} and Q4\textsubscript{WC} group (Fig 3).

Kaplan-Meier curve analysis with a 1-year landmark showed that CD/NFMI more frequently occurred in the low-BMI (Q1\textsubscript{BMI} and Q2\textsubscript{BMI}) and low-WC (Q1\textsubscript{WC} and Q2\textsubscript{WC}) groups compared to the high-BMI (Q3\textsubscript{BMI} and Q4\textsubscript{BMI}) and high-WC (Q3\textsubscript{WC} and Q4\textsubscript{WC}) groups, whereas there was no difference in the occurrence of CD/NFMI among the groups stratified by BMI and by WC 1 year after the index PCI. In contrast, there was no difference in the occurrence of MACEs in the groups stratified by BMI 1 year before or after the index PCI, whereas MACEs occurred more frequently in the Q1\textsubscript{WC} group than in any other groups stratified by WC, and MACEs occurred least frequently in the Q3\textsubscript{WC} group, both 1 year before and after the index PCI (Fig 4).
Table 1. Baseline and angiographic characteristics of the study population.

| Clinical characteristics                                      | N = 1421 |
|---------------------------------------------------------------|----------|
| Age (years)                                                   | 63.5 ± 10.6 |
| Male sex                                                      | 949 (66.8%) |
| Center 2                                                       | 453 (31.9%) |
| Diabetes mellitus                                             | 465 (32.7%) |
| Hypertension                                                  | 879 (61.9%) |
| CKD (eGFR < 60 mL/min/1.73 m²)                                | 236 (16.6%) |
| Current smoking                                               | 367 (25.9%) |
| Past history of PCI                                           | 233 (16.4%) |
| Clinical diagnosis                                            |          |
| Stable angina                                                 | 399 (28.1%) |
| Unstable angina                                               | 744 (52.4%) |
| NSTEMI                                                        | 183 (12.9%) |
| STEMI                                                         | 95 (6.7%) |
| Systolic blood pressure (mmHg)                                | 134.3 ± 23.0 |
| Diastolic blood pressure (mmHg)                               | 77.4 ± 12.0 |
| Body mass index (kg/m²)                                       | 24.9 ± 3.0 |
| Waist circumference (cm)                                      | 89.8 ± 8.1 |
| Waist-Height ratio                                            | 0.55 ± 0.06 |
| Laboratory tests                                              |          |
| Hemoglobin (g/dl)                                             | 13.4 ± 1.8 |
| Total cholesterol (mg/dl)                                     | 168.1 ± 40.0 |
| LDL cholesterol (mg/dl)                                       | 96.0 (75.0, 119.0) |
| HDL cholesterol (mg/dl)                                       | 40.0 (34.0, 47.7) |
| Triglyceride (mg/dl)                                          | 117.0 (84.0, 169.0) |
| HgA1c (%)                                                     | 6.1 (5.7, 6.9) |
| hsCRP (mg/dl)                                                 | 0.12 (0.05, 0.42) |
| eGFR (ml/min/1.73 m²)                                         | 77.3 ± 18.3 |
| Post PCI medications                                          |          |
| Statin                                                        | 1192 (84.1%) |
| Angiotensin blockers                                          | 1050 (74.0%) |
| Beta-blockers                                                 | 893 (63.0%) |
| LVMI (kg/m²)                                                  | 102.8±32.2 |
| LV ejection fraction (%)                                      | 68.8 ± 9.2 |
| Duration of DAPT (months)                                     | 18 (11, 34) |
| Duration of follow-up (months)                                | 29 (13, 41) |
| Angiographic characteristics                                  |          |
| Number of coronary arteries narrowed                           | 818 (57.8%) |
| 1                                                             | 428 (30.2%) |
| 3                                                             | 170 (12.0%) |
| Coronary arteries involved                                    |          |
| LMCA                                                         | 84 (5.9%) |
| LAD                                                          | 992 (70.1%) |
| LCX                                                          | 505 (35.7%) |
| RCA                                                          | 594 (41.9%) |
| Complete revascularization                                    | 1258 (88.6%) |

(Continued)
Relationship between the obesity indexes and clinical outcomes

The multiple Cox regression models with a nonlinear restricted cubic spline fit for the obesity indexes showed that simulated log-transformed hazard ratios (LogHRs) for CD/NFMI were only linearly associated with both BMI and WC. The simulated LogHRs for TVR and MACEs were not significantly associated with BMI in the model. In contrast, the LogHRs for TVR and MACEs gradually decreased until WC values indicating mild central obesity were reached (WC of 91 cm for TVR and 93 cm for MACE), and then the values gradually increased thereafter, and the U-shape biphasic regression spline fit for WC significantly improved the performance of the whole models predicting for both the risk of TVR and that of MACE (Fig 5).

Multiple Cox regression analyses showed that the risk of CD/NFMI was significantly associated with WC and marginally associated with BMI, with a linear assumption but not with a

### Table 1. (Continued)

| Number of stents implanted | N = 1421 |
|----------------------------|----------|
| 1                          | 645 (45.6%) |
| 2                          | 370 (26.1%) |
| ≥3                         | 401 (28.3%) |
| Average stent diameters (mm)| 3.1 (3.0, 3.5) |
| Total stent length (mm)    | 41 (24, 71) |
| Types of stents            |          |
| Paclitaxel                 | 245 (17.3%) |
| Sirolimus                  | 321 (22.7%) |
| Everolimus                 | 878 (62.0%) |
| Others                     | 17 (1.2%)  |
| Second generation DES      | 892 (63.0%) |

Data are shown as the mean ± SD or n (%).

Data with a skewed distribution are presented with the median (interquartile range)

CKD, chronic kidney diseases; PCI, percutaneous coronary intervention; LDL, low density lipoprotein; HDL, high density lipoprotein; hsCRP, highly sensitive C-reactive protein; eGFR, estimated glomerular filtration rate; LMCA, left main coronary artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; DES, drug eluting stent.

https://doi.org/10.1371/journal.pone.0208817.t001

**Fig 1.** Overall incidence of cardiac events after PCI, based on obesity indexes. There were no differences in the overall frequencies of CD, NFMI, TVR and MACE among the groups, based on BMI. The occurrences of CD and NFMI were marginally more frequent in the Q1WC and Q2WC groups than were those in the Q3WC and Q4WC groups, whereas the overall incidences of TVRs and MACEs were lowest in the Q3WC group and showed biphasic relations with WC.

https://doi.org/10.1371/journal.pone.0208817.g001
nonlinear assumption. In contrast, the risk of MACE was significantly associated with WC in both linear and nonlinear assumptions; however, it was not significantly associated with BMI (Table 2).

When BMI and WC were included together as linear fits in the multivariate Cox-regression models, the associations of both BMI and WC with the risk of CD/NFMI were weakened by one another’s presence, although WC showed a slightly stronger association ($\chi^2 = 1.73$, $p = 0.188$) than did BMI ($\chi^2 = 0.55$, $p = 0.459$; S3 Table). However, the presence of BMI in the
model did not weaken the association between WC and the risk of MACE, whereas BMI was not associated with the risk of MACE (S2 Fig. and S3 Table). There was no significant interaction between BMI and WC, in terms of their relationship with the risk of both CD/NFMI ($p = 0.488$) and MACE ($p = 0.667$; S4 Table).

**Discussion**

In this study, a beneficial effect of mild to moderate obesity on CD/NFMI was evident using both obesity indexes, BMI and WC, although it was more obvious with WC. In contrast, a beneficial effect on TVR-driven MACEs was not observed when mild obesity was defined by BMI; however, such an effect was observed when it was defined by WC. The lower CD/NFMI rates were observed in obese patients, based on both BMI and WC, until 1 year after the index PCI. However, the beneficial effect of mild central obesity defined by WC was observed on MACE throughout the observation duration. The risk of CD/NFMI was linearly associated with both obesity indexes, BMI and WC. There was a U-shaped relationship between the risk of TVR/MACE and WC, whereas there was no relationship between the risk of TVR/MACEs and BMI.

Although obesity has been an established risk factor for CVDs for a long time, studies have repeatedly shown that obesity was associated with better prognosis in patients with CVDs [6]. Beneficial effects of obesity on clinical outcomes have also been reported in many studies of patients undergoing PCI [8]. A meta-analysis including studies from the bare-metal stent era showed a U-shaped relationship between BMI and mortality in patients undergoing PCI [16]. In a recent large-scale cohort study from the U.K., a negative association between BMI and mortality after DES implantation was observed [17]. However, debates arose because most studies reporting these beneficial effects of obesity used BMI as the obesity index. In fact,
many studies have shown that central obesity or abdominal adiposity, as measured by WC or the waist-to-hip ratio, was linearly associated with a higher risk of mortality after PCI [18]. Several studies have also reported that low BMI and central obesity are associated with a high mortality rate among patients with MI [19–21], implying that BMI is not an adequate indicator of true adiposity.

Our results showed that higher BMI was linearly associated with a lower risk of CD and NFMI but not associated with a risk of TVR and TVR-driven MACEs. Similarly, Park et al.[8] reported that the incidence of all-cause deaths and MACEs, including CD, NFMI, stent thrombosis and stroke, decreased as BMI increased. Several studies have reported no association between TVR and BMI after a short-term observation [22]. Increasing WC was also linearly associated with a lower risk of CD or NFMI. However, unlike BMI, WC had a U-shape biphasic relationship with TVR/MACEs. The increased risk of TVR/MACEs in patients with severe central obesity is consistent with the classical notion of central obesity as a risk factor for CVD and mortality. In contrast, a negative association between the risk of CD/NFMI and WC and a decreased risk of TVR in patients with mild central obesity may be unexpected, given that many studies have reported that central obesity is a predictor of cardiovascular
mortality in patients with CAD [18]. The relationship between WC and cardiovascular outcome after PCI has been less frequently reported than that of BMI has, and to date, no study has reported an association between high WC and better cardiovascular outcomes after PCI. However, high adiposity itself has been reported as a predictor of good prognosis among patients with CADs. Lavie et al.[12, 23] reported that a high percentage of body fat, which was measured using the sum of the skinfold method, was associated with a lower mortality rate among patients with stable CAD. They suggested that the obesity paradox may also apply to central obesity, as high body fat content, lean body mass and fitness were the actual contributors to the obesity paradox in patients with CAD [24, 25]. Our results may also serve as an evidence against criticism stating that the obesity paradox is misleading because BMI is not an adequate indicator of true adiposity. A high WC at the time of the index PCI may exert not
only beneficial effects on clinical outcomes after PCI (as observed with a high BMI) but also might be a better predictor of TVR than is BMI. The correlation between BMI and WC in our study was not strong ($R^2 = 0.47$) compared with that in a previous study ($R^2 = 0.61$) [26]. This result is likely associated with a difference in the body compositions of the population in which the studies were performed. The mean BMI and WC levels were lower (24.8 kg/m$^2$ and 90 cm, respectively) in our cohort than in a previous study (30.7 kg/m$^2$ and 108 cm, respectively), which means that not many severely obese patients were included in this study. Thus, BMI may reflect a lean body mass, which is associated with a better prognosis in patients with CAD, which may explain why there was no distinct association between TVR and BMI in our results.

Kaplan-Meier curve analysis with 12-month’s landmark showed that the occurrence of CD and NFMI was significantly different, based on both BMI and WC in the early period of observation but not in the late period. In contrast, TVR and MACEs showed a distinctive biphasic relationship with WC after 1 year of observation, particularly TVR, which demonstrated significantly different event rates only 1 year after the index PCI. A recent meta-analysis also
showed that the beneficial effects of morbid obesity in patients with established CAD did not last in long-term follow-up periods [27]. Our results may also imply that there are two different underlying reasons for the beneficial effects of obesity on CD/NFMI in the early period and TVR-driven MACE in the late period of observation.

One explanation for these results may be found in our study population who underwent PCI. The classical notion of WC predicting CVD and mortality originated from large population-based studies, in which the cardiovascular events were less frequent than they were in studies of patients with advanced CAD, such as ours, and most cardiovascular events were related to the natural progression of atherosclerotic plaque. However, unlike a general population, patients undergoing PCI have risk factors for CAD progression, such as hypertension, diabetes and smoking more frequently, and they also have various clinical features that could worsen their clinical outcomes, including elevated inflammation, reduced myocardial function, low exercise capacity and poor medication compliance. Therefore, higher metabolic reserves and less cachexia would likely outweigh the cardiovascular consequences of obesity within 1 year of the index PCI, which is not sufficient for atherosclerosis to progress but is sufficient for left ventricular remodeling and heart failure to occur. Small volumes of distribution may also be associated with higher bleeding risk, thereby increasing the early cardiovascular event rates in nonobese patients, shortly after they were introduced to DAPT. Numasawa et al. [28] reported more cases of in-hospital complications after PCI in patients with low BMI because of the higher risk of bleeding. Although BMI may reflect lean body mass rather than reflecting adiposity, and WC primarily presents as central adiposity, both adiposity and lean body mass could serve as metabolic reserves. These factors may explain the negative association between the risk of CD/NFMI and both obesity indexes. The fact that the associations between BMI and WC and the risk of CD/NFMI were weakened by one another’s presence, without significant interactions with one another in the multivariate Cox-regression model, may also indicate the similarity in the underlying mechanism for the association between low BMI and WC and the risk of CD/NFMI.

The biphasic relationship between TVR/MACEs and WC after 1 year of observation may be explained by the high positive remodeling rate of coronary arteries in obese patients. Unlike cardiovascular events occurring through slow atherosclerotic process in the general population, cardiovascular events occurring in patients who underwent PCI are most frequently associated with in-stent restenosis through rapidly progressing neo-atherosclerosis. Using intravascular ultrasonography, Kang et al.[29] determined that obese patients tended to have larger coronary reference diameters and undergo PCI with larger diameter stents. Kim et al. [30] also reported that insulin resistance was associated with high positive remodeling rates. Given that most TVR results from in-stent restenosis and that TVR rates differed only in the late period of observation, the pro-atherosclerotic effects of obesity and larger luminal gains after PCI may balance out, thereby leading to the observation of the lowest risk of TVR in patients with mild central obesity. Furthermore, the higher rates of optimal medical therapy may also contribute to a lower risk of TVR/MACEs in patients with mild central obesity. Studies have reported that optimal medical therapies are more frequently administered to obese patients than to nonobese patients, due to high blood pressure levels and lipid profile levels [31].

To date, many studies have reported the impact of obesity defined by a single measurement of BMI or WC on clinical outcomes after PCI. However, because the body composition and adiposity of patients may change during the observation periods, and because the changes may be more closely related to differences in outcome, it is difficult to make any practical lifestyle recommendations about body weight to patients after PCI using data from these studies. Although few longitudinal data are currently available, in a small-scale retrospective study,
Kang et al. [32] reported that weight loss > 5% was associated with worse outcomes in patients with acute MI after successful PCI. Larger-scale prospective studies are necessary to develop a practical recommendation regarding obesity for patients undergoing PCI.

**Limitations**

This study has several limitations. First, only two high-volume PCI centers located around Seoul participated in this study; therefore, a referral bias may be present. The prevalence of obesity (and other cardiovascular risk factors) and the event rates may not represent those of the entire population undergoing PCI in South Korea. Second, only a small number of patients with a high BMI or WC were included because of the low incidence of obesity in a typical Asian population compared with a typical Western population. The total sample size was also relatively small in our study, compared with those in population-based studies and other multicenter registry studies. Third, the obesity indexes were measured only once; therefore, important changes in the levels of obesity may have occurred during the long observation period and may have caused the differences in outcomes among the groups. Fourth, we did not measure body composition and hip circumference, which may help fortify or disprove our findings. Finally, we did not include any measurements that may provide some mechanistic insights on the paradoxical beneficial effects of obesity, other than the landmark analysis. Therefore, we cannot make any recommendations regarding body weight or WC for patients undergoing PCI based on the findings from this study.

**Conclusion**

In patients undergoing PCI, both obesity indexes, BMI and WC, were associated with a lower risk of CD/NFMI, although WC may be a slightly better indicator of the beneficial effects of obesity than is BMI. The risk of CD/NFMI was linearly associated with both BMI and WC; however, the biphasic U-shaped relationship was observed only between the risk of TVR-driven MACE and WC. Our results suggest that the better cardiovascular outcomes observed in obese patients undergoing PCI were not associated with high BMI, reflecting high lean body mass, but were associated with true adiposity and that WC may be a better indicator of the paradoxical beneficial effects of obesity than is BMI in patients undergoing PCI. The differences in the relationships of both BMI and WC with the clinical outcomes, according to time, may also suggest that the reasons underlying the beneficial effects of obesity may differ between the early and the late period of observation. Studies including serial measurements of the obesity indexes are required to determine the underlying causes of the beneficial effect of obesity and produce a recommendation for lifestyle modifications for obese patients undergoing PCI.

**Supporting information**

**S1 Fig. Cumulative incidences of CD and NFMI after PCI based on obesity indexes.** CD occurred more frequently in the high WC groups (Q3\textsubscript{WC} and Q4\textsubscript{WC}) than in the low WC groups (Q1\textsubscript{WC} and Q2\textsubscript{WC}), whereas there was no difference in the risk of CD among the groups, according to BMI. The incidence of NFMI was only marginally higher in the low WC and BMI groups.

CD, cardiac death; NFMI, nonfatal myocardial infarction; BMI body mass index; WC, waist circumference.

(TIF)

**S2 Fig. Three-dimensional depiction of the relationship of the risk of clinical events with both BMI and WC.** The opaquer sheaths represent the surfaces of log (HR) from multivariate
Cox-regression, and the less opaque sheaths represent the surfaces of upper and lower 95% confidence interval limits. The upper panel (green sheaths) represents the risk of MACE, and the lower panel (purple) represents the risk of CD/NFMI. HRs were derived from multivariate Cox-regression models, and restrictive cubic spline fits for obesity indexes were used in the upper panel and linear fits were used in the lower panel. Image A and B in each upper and lower panel are 90-degree rotational views of one another.

When both BMI and WC were included in the models, the risk of MACE was only associated with WC, whereas the risk of CD/NFMI was not associated with both WC and BMI. There were no significant interactions between BMI and WC in the regression models for the risk of CD/NFMI ($p = 0.488$) and MACE ($p = 0.667$).

- Adjusted for age, sex, diabetes mellitus, hypertension, current smoking, chronic kidney disease, history of PCI, STEMI, stent type (1st vs. 2nd generation), center, TSL, average stent diameter, complete revascularization and the duration of DAPT. Each model was reduced through a backward variable selection process.

CD, cardiac death; NFMI, nonfatal myocardial infarction; MACE, major adverse cardiac event; BMI, body mass index; and WC, waist circumference; df, degrees of freedom.

(TIF)

S1 Table. Baseline characteristics of the study population by the groups based on BMI and those based on WC. Data were shown in mean ± SD or n (%).

Data with a skewed distribution were presented with median (1st quartile value and 3rd quartile value)

BMI; body mass index; WC, waist circumference; PCI, percutaneous coronary intervention; LDL, low density lipoprotein; HDL, high density lipoprotein; hsCRP, highly sensitive C-reactive protein; eGFR, estimated glomerular filtration rate; LMCA, left main coronary artery; LAD, left anterior descending artery; LCX, left circumflex artery; RCA right coronary artery; DES, drug eluting stent.

(DOCX)

S2 Table. Overall frequency of clinical outcomes after PCI. Data are shown as number (%).

* Median (the first quartile, the third quartile)
† Cardiac death + Non-fatal MI + TVR

PCI, percutaneous coronary intervention; BMI, body mass index; WC, waist circumference; MI, myocardial infarction; TVR, target vessel revascularization; MACE, major adverse cardiac event.

(DOCX)

S3 Table. Multivariate Cox-regression analysis for both BMI and WC on the clinical outcomes. Models were reduced by a backward variable selection process (cut-off point, $p < 0.05$) and BMI and WC were set to remain in the final model.

* Restrictive cubic spline fits for BMI and WC were used in the model (df = 4).

CD, cardiac death; NFMI, non-fatal myocardial infarction; MACE, major adverse cardiac event; BMI, body mass index; WC, waist circumference; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; DAPT, dual antiplatelet agent therapy.

(DOCX)

S4 Table. Interaction between BMI and WC on the clinical outcomes. Models were reduced by a backward variable selection process (cut-off point, $p < 0.05$) and BMI and WC were set to remain in the final model.

* Restrictive cubic spline fits for BMI and WC were used in the model (df = 4).

CD, cardiac death; NFMI, non-fatal myocardial infarction; MACE, major adverse cardiac
event; BMI, body mass index; WC, waist circumference; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; DAPT, dual antiplatelet agent therapy.

(DOCX)

Acknowledgments

This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) & funded by the Korean government (MSIT) (No. 2017M3A9E2064741).

Author Contributions

Conceptualization: Uram Jin, Hong-Seok Lim, Young-Hyo Lim.

Data curation: Yonggu Lee, Uram Jin, Young-Hyo Lim.

Formal analysis: Yonggu Lee, Uram Jin.

Investigation: Yonggu Lee.

Methodology: Yonggu Lee.

Software: Yonggu Lee.

Supervision: Hong-Seok Lim, Young-Hyo Lim.

Validation: Yonggu Lee.

Visualization: Yonggu Lee, Won Moo Lee.

Writing – original draft: Hong-Seok Lim.

Writing – review & editing: Yonggu Lee, Won Moo Lee.

References

1. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5):968–77. Epub 1983/05/01. PMID: 6219830.

2. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. The New England journal of medicine. 1995; 333(11):677–85. Epub 1995/09/14. https://doi.org/10.1056/NEJM199509143331101 PMID: 7637744.

3. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. The New England journal of medicine. 2006; 355(8):779–87. Epub 2006/08/24. https://doi.org/10.1056/NEJMoa054017 PMID: 16926276.

4. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. Jama. 1999; 282(22):2131–5. Epub 1999/12/11. PMID: 10591334.

5. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009; 53(21):1925–32. Epub 2009/05/23. https://doi.org/10.1016/j.jacc.2008.12.068 PMID: 19460605.

6. Lavie CJ, De Schutter A, Parto P, Jahangir E, Kokkinos P, Ortega FB, et al. Obesity and Prevalence of Cardiovascular Diseases and Prognosis-The Obesity Paradox Updated. Progress in cardiovascular diseases. 2016; 58(5):537–47. Epub 2016/01/31. https://doi.org/10.1016/j.pcad.2016.01.008 PMID: 26826295.

7. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. The New England journal of medicine. 1999; 341(15):1097–105. Epub 1999/10/08. https://doi.org/10.1056/NEJM199910073411501 PMID: 10511607.

8. Park DW, Kim YH, Yun SC, Ahn JM, Lee JY, Kim WJ, et al. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention. Circ Cardiovasc Interv. 2013; 6(2):146–53. https://doi.org/10.1161/CIRCINTERVENTIONS.112.000662 PMID: 23532553.
9. Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, et al. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. Am Heart J. 2006; 151(1):168–75. https://doi.org/10.1016/j.ahj.2005.03.024 PMID: 16368312.

10. Romero-Corral A, Somers VK, Sierra-Johnson J, Jensen MD, Thomas RJ, Squires RW, et al. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. European heart journal. 2007; 28(17):2087–93. Epub 2007/07/13. https://doi.org/10.1093/eurheartj/ehm243 PMID: 17626030.

11. Kim TN, Park MS, Lim KI, Yang SJ, Yoo HJ, Kang HJ, et al. Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness: The Korean Sarcopenic Obesity Study (KOSOS). Diabetes Res Clin Pract. 2011; 93(2):285–91. https://doi.org/10.1016/j.diabres.2011.06.013 PMID: 21752483.

12. Lavie CJ, De Schutter A, Patel DA, Romero-Corral A, Artham SM, Milani RV. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the "obesity paradox". J Am Coll Cardiol. 2012; 60(15):1374–80. Epub 2012/09/11. https://doi.org/10.1016/j.jacc.2012.05.037 PMID: 22958953.

13. Iannuzzi-Suich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002; 57(12):M772–7. PMID: 12456735.

14. Brenner DR, Teplyo K, Eny KM, Cahill LE, El-Sohemy A. Comparison of body mass index and waist circumference as predictors of cardiometabolic health in a population of young Canadian adults. Diabetology & metabolic syndrome. 2010; 2(1):28. Epub 2010/05/13. https://doi.org/10.1186/1758-5996-2-28 PMID: 20459858; PubMed Central PMCID: PMC2883969.

15. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Farb A, et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoint Data Standards). J Am Coll Cardiol. 2015; 66(4):403–69. Epub 2015/01/03. https://doi.org/10.1016/j.jacc.2014.12.018 PMID: 25557322.

16. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006; 368(9536):666–78. Epub 2006/08/22. https://doi.org/10.1016/S0140-6736(06)69251-9 PMID: 16920472.

17. Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA, et al. The Relationship of Body Mass Index to Percutaneous Coronary Intervention Outcomes: Does the Obesity Paradox Exist in Contemporary Percutaneous Coronary Intervention Cohorts? Insights From the British Cardiovascular Intervention Society Registry. JACC Cardiovasc Interv. 2017; 10(13):1283–92. https://doi.org/10.1016/j.jcin.2017.03.013 PMID: 28683933.

18. Coutinho T, Goel K, Correa de Sa D, Kragelund C, Kanaya AM, Zeller M, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011; 57(19):1877–86. Epub 2011/05/07. https://doi.org/10.1016/j.jacc.2011.10.058 PMID: 21545944.

19. Coutinho T, Goel K, Correa de Sa D, Carter RE, Hodge DO, Kragelund C, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of "normal weight central obesity". J Am Coll Cardiol. 2013; 61(5):553–60. Epub 2013/02/02. https://doi.org/10.1016/j.jacc.2012.10.035 PMID: 23369419.

20. Zeller M, Steg PG, Ravisly J, Longis L, Laurent Y, Sicard P, et al. Relation between body mass index, waist circumference, and death after acute myocardial infarction. Circulation. 2008; 118(5):482–90. Epub 2008/07/16. https://doi.org/10.1161/CIRCULATIONAHA.107.753483 PMID: 18625893.

21. Lee SH, Park JS, Kim W, Shin DG, Kim YJ, Kim DS, et al. Impact of body mass index and waist-to-hip ratio on clinical outcomes in patients with ST-segment elevation acute myocardial infarction (from the Korean Acute Myocardial Infarction Registry). Am J Cardiol. 2008; 102(8):957–65. Epub 2008/10/22. https://doi.org/10.1016/j.amjcard.2008.06.022 PMID: 18929693.

22. Diletti R, Garcia-Garcia HM, Bouxant C, Van Mieghem NM, van Geuns RJ, Muramatsu T, et al. Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program. Catheter Cardiovasc Interv. 2015; 85(6):952–8. https://doi.org/10.1002/cdiu.25828 PMID: 25689692.

23. Lavie CJ, De Schutter A, Patel D, Artham SM, Milani RV. Body composition and coronary heart disease mortality—an obesity or a lean paradox? Mayo Clinic proceedings. 2011; 86(9):857–64. https://doi.org/10.4065/mcp.2011.09.002 PMID: 21785897; PubMed Central PMCID: PMC3257992.

24. McCauley PA, Beavers KM. Contribution of cardiorespiratory fitness to the obesity paradox. Progress in cardiovascular diseases. 2014; 56(4):434–40. https://doi.org/10.1016/j.pcad.2013.09.006 PMID: 24438735.
25. De Schutter A, Lavie CJ, Milani RV. The impact of obesity on risk factors and prevalence and prognosis of coronary heart disease - the obesity paradox. Progress in cardiovascular diseases. 2014; 56(4):401–8. Epub 2014/01/21. https://doi.org/10.1016/j.pcad.2013.08.003 PMID: 24438731.

26. Gierach M, Gierach J, Ewertowska M, Arndt A, Junik R. Correlation between Body Mass Index and Waist Circumference in Patients with Metabolic Syndrome. ISRN Endocrinol. 2014; 2014:514589. https://doi.org/10.1155/2014/514589 PMID: 24729884; PubMed Central PMCID: PMCPMC3960736.

27. Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW, Mauri L. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015; 101(20):1631–8. Epub 2015/05/31. https://doi.org/10.1136/heartjnl-2014-307119 PMID: 26025084.

28. Numasawa Y, Kohsaka S, Miyata H, Kawamura A, Noma S, Suzuki M, et al. Impact of body mass index on in-hospital complications in patients undergoing percutaneous coronary intervention in a Japanese real-world multicenter registry. PLoS one. 2015; 10(4):e0124399. Epub 2015/04/16. https://doi.org/10.1371/journal.pone.0124399 PMID: 25874887; PubMed Central PMCID: PMCPMC4397046.

29. Kang SJ, Mintz GS, Witzenbichler B, Metzger DC, Rinaldi MJ, Duffy PL, et al. Effect of obesity on coronary atherosclerosis and outcomes of percutaneous coronary intervention: grayscale and virtual histology intravascular ultrasound substudy of assessment of dual antiplatelet therapy with drug-eluting stents. Circ Cardiovasc Interv. 2015; 8(1). Epub 2015/01/02. https://doi.org/10.1161/CIRCINTERVENTIONS.114.001392 PMID: 25552564.

30. Kim SH, Moon JY, Lim YM, Kim KH, Yang WI, Sung JH, et al. Association of insulin resistance and coronary artery remodeling: an intravascular ultrasound study. Cardiovasc Diabetol. 2015; 14:74. Epub 2015/06/07. https://doi.org/10.1186/s12933-015-0238-8 PMID: 26047939; PubMed Central PMCID: PMCPMC4472609.

31. Kang WY, Jeong MH, Ahn YK, Kim JH, Chae SC, Kim YJ, et al. Obesity paradox in Korean patients undergoing primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. J Cardiol. 2010; 55(1):84–91. Epub 2010/02/04. https://doi.org/10.1016/j.jcc.2009.10.004 PMID: 20122553.

32. Kang WY, Hwang SH, Hwang SH, Kim W, Park KH, Hong YJ, et al. Effects of weight change on clinical outcomes in overweight and obese patients with acute myocardial infarction who underwent successful percutaneous coronary intervention. Chonnam Med J. 2012; 48(1):32–8. https://doi.org/10.4068/cmj.2012.48.1.32 PMID: 22570813; PubMed Central PMCID: PMCPMC3341435.